These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21255398)

  • 1. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.
    Xu H; Yan M; Patra J; Natrajan R; Yan Y; Swagemakers S; Tomaszewski JM; Verschoor S; Millar EK; van der Spek P; Reis-Filho JS; Ramsay RG; O'Toole SA; McNeil CM; Sutherland RL; McKay MJ; Fox SB
    Breast Cancer Res; 2011 Jan; 13(1):R9. PubMed ID: 21255398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
    Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
    Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells.
    Atienza JM; Roth RB; Rosette C; Smylie KJ; Kammerer S; Rehbock J; Ekblom J; Denissenko MF
    Mol Cancer Ther; 2005 Mar; 4(3):361-8. PubMed ID: 15767545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas.
    Deb S; Xu H; Tuynman J; George J; Yan Y; Li J; Ward RL; Mortensen N; Hawkins NJ; McKay MJ; Ramsay RG; Fox SB
    Br J Cancer; 2014 Mar; 110(6):1606-13. PubMed ID: 24548858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability.
    Yun J; Song SH; Kang JY; Park J; Kim HP; Han SW; Kim TY
    Nucleic Acids Res; 2016 Jan; 44(2):558-72. PubMed ID: 26420833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.
    Lamy PJ; Fina F; Bascoul-Mollevi C; Laberenne AC; Martin PM; Ouafik L; Jacot W
    Breast Cancer Res; 2011 Feb; 13(1):R15. PubMed ID: 21288332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
    N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
    Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.
    Cheng Q; Chang JT; Geradts J; Neckers LM; Haystead T; Spector NL; Lyerly HK
    Breast Cancer Res; 2012 Apr; 14(2):R62. PubMed ID: 22510516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
    Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL
    Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
    BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of RAD21 Induces Senescence of MDA-MB-231 Human Breast Cancer Cells Through RB1 Pathway Activation Via c-Myc Downregulation.
    Zhu S; Zhao L; Li Y; Hou P; Yao R; Tan J; Liu D; Han L; Huang B; Lu J; Zhang Y
    J Cell Biochem; 2016 Jun; 117(6):1359-69. PubMed ID: 26529363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.
    Singel SM; Cornelius C; Batten K; Fasciani G; Wright WE; Lum L; Shay JW
    Clin Cancer Res; 2013 Apr; 19(8):2061-70. PubMed ID: 23479679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.
    Arora A; Parvathaneni S; Aleskandarany MA; Agarwal D; Ali R; Abdel-Fatah T; Green AR; Ball GR; Rakha EA; Ellis IO; Sharma S; Madhusudan S
    Mol Cancer Ther; 2017 Jan; 16(1):239-250. PubMed ID: 27837030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
    Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
    Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.
    Yang YF; Lee YC; Wang YY; Wang CH; Hou MF; Yuan SF
    Kaohsiung J Med Sci; 2019 Jul; 35(7):408-416. PubMed ID: 31001932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.